Benjamin Weixler1,2, Carsten T Viehl1,3, Rene Warschkow4,5, Ulrich Guller6,7, Michaela Ramser1, Guido Sauter8,9, Markus Zuber10. 1. Department of Surgery, University Hospital Basel, Basel, Switzerland. 2. Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Surgery, Hospital Center Biel, Biel/Bienne, Switzerland. 4. Department of Surgery, Kantonsspital St Gallen, St Gallen, Switzerland. 5. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany. 6. Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland. 7. University Clinic for Visceral Surgery and Medicine, Inselspital Berne, University of Berne, Berne, Switzerland. 8. Department of Pathology, University Hospital Basel, Basel, Switzerland. 9. Department of Pathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 10. Department Surgery, Cantonal Hospital Olten, Olten, Switzerland.
Abstract
IMPORTANCE: Small nodal tumor infiltrates (SNTI; isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BMM) were independently described as prognostic factors in patients with colon cancer. OBJECTIVE: To examine the association between the occurrence of SNTI and BMM as well as their prognostic relevance. DESIGN, SETTING, AND PARTICIPANTS: This prospective study was conducted at 3 university-affiliated institutions in Switzerland between May 2000 and December 2006. Statistical analyses were performed in October 2016. A total of 122 patients with stage I to III colon cancer were included. Follow-up time exceeded 6 years, with no patients lost to follow-up. INTERVENTIONS: Bone marrow aspiration from the iliac crests and in vivo sentinel lymph node mapping were performed during open standard oncological resection. Bone marrow aspirates were stained with the pancytokeratin marker A45-B/B3. All sentinel lymph nodes underwent multilevel sectioning and were stained with hematoxylin-eosin and the pancytokeratin marker AE1/AE3. MAIN OUTCOMES AND MEASURES: Association of SNTI in sentinel lymph nodes and BMM in patients with stage I to III colon cancer and the prognostic effect on disease-free survival (DFS) and overall survival (OS). RESULTS: Of the 122 patients, 63 (51.6%) were female, with a mean (SD) age of 71.2 (11.7) years. Small nodal tumor infiltrates and BMM were found in a total of 21 patients (17.2%) and 46 patients (37.7%), respectively. The occurrence of BMM was not associated with the presence of SNTI by standard correlation (κ, -0.07; 95% CI, -0.29 to 0.14; P = .49) nor by univariate logistic regression analysis (odds ratio, 0.64; 95% CI, 0.22-1.67; P = .37) or multivariate logistic regression analysis (odds ratio, 1.09; 95% CI, 0.34-3.28; P = .88). The presence of SNTI was an independent negative prognostic factor for DFS (hazard ratio [HR], 2.93; 95% CI, 1.24-6.93; P = .02) and OS (HR, 4.04; 95% CI, 1.56-10.45; P = .005), as was BMM (HR, 2.07; 95% CI, 1.06-4.06; P = .04; and HR, 2.68; 95% CI, 1.26-5.70; P = .01; respectively). The combined detection of BMM and SNTI demonstrated the poorest DFS (HR, 6.73; 95% CI, 2.29-19.76; P = .006) and OS (HR, 5.96; 95% CI, 1.66-21.49; P = .03). CONCLUSIONS AND RELEVANCE: This study demonstrates no association between the occurrence of SNTI and BMM in patients with stage I to III colon cancer. However, both SNTI and BMM are independent negative prognostic factors regarding DFS and OS, and the occurrence of both is associated with significantly worse prognosis compared with either one of them. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00826579.
IMPORTANCE: Small nodal tumor infiltrates (SNTI; isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BMM) were independently described as prognostic factors in patients with colon cancer. OBJECTIVE: To examine the association between the occurrence of SNTI and BMM as well as their prognostic relevance. DESIGN, SETTING, AND PARTICIPANTS: This prospective study was conducted at 3 university-affiliated institutions in Switzerland between May 2000 and December 2006. Statistical analyses were performed in October 2016. A total of 122 patients with stage I to III colon cancer were included. Follow-up time exceeded 6 years, with no patients lost to follow-up. INTERVENTIONS: Bone marrow aspiration from the iliac crests and in vivo sentinel lymph node mapping were performed during open standard oncological resection. Bone marrow aspirates were stained with the pancytokeratin marker A45-B/B3. All sentinel lymph nodes underwent multilevel sectioning and were stained with hematoxylin-eosin and the pancytokeratin marker AE1/AE3. MAIN OUTCOMES AND MEASURES: Association of SNTI in sentinel lymph nodes and BMM in patients with stage I to III colon cancer and the prognostic effect on disease-free survival (DFS) and overall survival (OS). RESULTS: Of the 122 patients, 63 (51.6%) were female, with a mean (SD) age of 71.2 (11.7) years. Small nodal tumor infiltrates and BMM were found in a total of 21 patients (17.2%) and 46 patients (37.7%), respectively. The occurrence of BMM was not associated with the presence of SNTI by standard correlation (κ, -0.07; 95% CI, -0.29 to 0.14; P = .49) nor by univariate logistic regression analysis (odds ratio, 0.64; 95% CI, 0.22-1.67; P = .37) or multivariate logistic regression analysis (odds ratio, 1.09; 95% CI, 0.34-3.28; P = .88). The presence of SNTI was an independent negative prognostic factor for DFS (hazard ratio [HR], 2.93; 95% CI, 1.24-6.93; P = .02) and OS (HR, 4.04; 95% CI, 1.56-10.45; P = .005), as was BMM (HR, 2.07; 95% CI, 1.06-4.06; P = .04; and HR, 2.68; 95% CI, 1.26-5.70; P = .01; respectively). The combined detection of BMM and SNTI demonstrated the poorest DFS (HR, 6.73; 95% CI, 2.29-19.76; P = .006) and OS (HR, 5.96; 95% CI, 1.66-21.49; P = .03). CONCLUSIONS AND RELEVANCE: This study demonstrates no association between the occurrence of SNTI and BMM in patients with stage I to III colon cancer. However, both SNTI and BMM are independent negative prognostic factors regarding DFS and OS, and the occurrence of both is associated with significantly worse prognosis compared with either one of them. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00826579.
Authors: Carsten T Viehl; Ulrich Guller; Christian T Hamel; Hans-Martin Riehle; Christian Plaass; Walter R Marti; Daniel Oertli; Markus Zuber Journal: World J Surg Date: 2006-03 Impact factor: 3.352
Authors: Igor Langer; Ulrich Guller; Mathias Worni; Gilles Berclaz; Gad Singer; Gabriel Schaer; Mathias K Fehr; Thomas Hess; Carsten Viehl; Lucio Bronz; Beate Schnarwyler; Edward Wight; Eduard Infanger; Daniel Burger; Ossi R Koechli; Markus Zuber Journal: Ann Surg Oncol Date: 2013-10-22 Impact factor: 5.344
Authors: Ingo Stoffels; Philipp Jansen; Maximilian Petri; Lukas Goerdt; Titus J Brinker; Klaus G Griewank; Thorsten D Poeppel; Dirk Schadendorf; Joachim Klode Journal: JAMA Netw Open Date: 2019-08-02
Authors: Benjamin Weixler; Sofia Teixeira da Cunha; René Warschkow; Nicolas Demartines; Ulrich Güller; Andreas Zettl; Alexander Vahrmeijer; Cornelis J H van de Velde; Carsten T Viehl; Markus Zuber Journal: World J Surg Date: 2021-01-29 Impact factor: 3.352
Authors: Michaela Ramser; Rene Warschkow; Carsten T Viehl; Christoph Kettelhack; Andreas Zettl; Leonard A Lobbes; Markus Zuber; Benjamin Weixler Journal: World J Surg Date: 2021-12-27 Impact factor: 3.352